Physician profile

Rixin Zhou

Hematology & Oncology · Las Vegas, NV

NPI 1962678136

$2,934.30

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$16.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Karyopharm Therapeutics INC. $2,250.00 2021
Lilly USA, LLC $155.08 2021-2022
Verastem, INC. $124.28 2020
Seagen INC. $109.31 2019
Incyte Corporation $71.99 2020
Abbvie INC. $64.51 2020-2023 Venclexta
Glaxosmithkline, LLC. $33.51 2021
Janssen Pharmaceuticals, INC $32.31 2019
Regeneron Healthcare Solutions, INC. $31.87 2021
Pfizer INC. $25.69 2019
Celgene Corporation $18.51 2020
E.R. Squibb & Sons, L.L.C. $17.24 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rixin Zhou

$2,934.30

in general payments reported 2019-2025

Years
2019-2023
Top company
Karyopharm Therapeutics INC.

https://glasscript.com/doctor/362098/rixin-zhou

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.